title: Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen.
authors.affiliation: First Department of Internal Medicine, Gifu University Graduate School of Medicine.
authors.forename: Naoe
authors.initials: N
authors.lastname: Goto
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
authors.forename: Masao
authors.initials: M
authors.lastname: Takemura
authors.forename: Takuro
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Shibata
authors.forename: Ryoko
authors.initials: R
authors.lastname: Mabuchi
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Nakamura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakamura
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Yamada
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Seishima
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takami
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Hisataka
authors.initials: H
authors.lastname: Moriwaki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012372:ROC Curve; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood*; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D047888:Receptors, Tumor Necrosis Factor, Type I; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone